| Document |
Document Title |
|
WO/2021/032687A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propa...
|
|
WO/2021/030542A1 |
The present disclosure provides a topical pharmaceutical formulation comprising uracil and a penetration enhancer, method of administration the same. Also provided is a method of treating or preventing dermatoses associated with the admi...
|
|
WO/2021/029158A1 |
The purpose of the present invention is to provide: a sulfonamide compound which has a high decomposition rate in response to near-ultraviolet rays and which generates a superacid bis-sulfonamide, and which is highly soluble in a resist ...
|
|
WO/2021/029450A1 |
The present invention relates to: a pyrimidine sulfonamide derivative disubstituted at a specific position with a trifluoroethoxy group; and a pharmaceutical composition which is for preventing or treating cancer and comprises same as an...
|
|
WO/2021/028316A1 |
The present invention relates to compounds of Formula (I), wherein A, R1, R2 n and p are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of ...
|
|
WO/2021/026672A1 |
Provided are compounds of Formula (I) and pharmaceutical acceptable salts thereof, which are inhibitors of WDR5. Also providing pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additio...
|
|
WO/2021/027647A1 |
A bridged heterocyclyl-substituted pyrimidine compound, a preparation method therefor, and pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method fo...
|
|
WO/2021/027502A1 |
Methods of treating malaria comprising administration of compounds of Formula (I') or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the com...
|
|
WO/2021/026884A1 |
Methods for treating malaria comprises administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the comp...
|
|
WO/2021/030623A1 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/025976A1 |
The present disclosure includes novel substituted cyclopropyl-2,2'-bipyrimidinyl compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infec...
|
|
WO/2021/022788A1 |
Disclosed is a method for refining 5-fluorouracil, comprising the following steps: dissolving 5-fluorouracil in an organic solvent, preferably DMSO, heating and stirring until dissolved; naturally cooling the filtrate until a crystal is ...
|
|
WO/2021/025975A1 |
The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type 2 diabetes mellitus.
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/024135A1 |
The present invention relates to an improved processses for synthesizing preparing substituted cyanophenoxy-pyrimidinyloxy-phenyl acrylate derivatives. The present invention specifically relates to an improved process for the preparation...
|
|
WO/2021/024260A1 |
The technology disclosed herein concerns compounds capable of binding to CB1Rs in the periphery and not in the CNS.
|
|
WO/2021/017996A1 |
Disclosed in the present invention are a phenylpiperazine quinazoline compound or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof. Specifically, the phenylpiperazine quinazoline compound ...
|
|
WO/2021/020362A1 |
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...
|
|
WO/2021/021634A1 |
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...
|
|
WO/2021/016929A1 |
Disclosed are cocrystal form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-Kɑ radiation, cocrystal form A has characteristic peaks represented by a 2θ degree at 8.1±0.2°, 12.2±0.2°, 13.3...
|
|
WO/2021/018226A1 |
A heterocyclic compound having the structure represented in formula I, and an application thereof. Experimental results show that the heterocyclic compound has thyroid hormone beta receptor agonistic activity, and may be used to treat an...
|
|
WO/2021/018834A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, m, n and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use fo...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/018017A1 |
Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/018270A1 |
Disclosed are a host compound applied to the field of organic electroluminescence, and an organic electroluminescent device using same. The molecular structural formula of the organic compound is LA-LB, wherein LA has a structure represe...
|
|
WO/2021/018833A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...
|
|
WO/2021/017597A1 |
Disclosed are a method for preparing a pyrimidine salicylic acid oxime ester compound and the use thereof as a herbicide, belonging to the technical field of herbicides, and relating to the use of the herbicide for selectively preventing...
|
|
WO/2021/013084A1 |
The present invention relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present invention are the compound shown in formula I, a pha...
|
|
WO/2021/012323A1 |
An electron transport material represented by the following formula (I), a preparation method therefor, use thereof in preparing an organic electroluminescent device, an organic electroluminescent device, an electronic display device and...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/009034A1 |
The present invention relates to a new intermediate useful in the synthesis of elagolix, to a process for obtaining same, to the use of said intermediate for preparing elagolix, and to a process for preparing elagolix making use of said ...
|
|
WO/2021/009568A1 |
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/007350A1 |
This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, met...
|
|
WO/2021/000884A1 |
The present invention relates to a 2-aminopyrimidine compound shown in formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof, preparation methods for the 2-aminopyrimidine compound, and the pharmaceutically acceptable...
|
|
WO/2021/000933A1 |
Provided are a class of compounds with pyrimidinone structure as chymase inhibitor drugs, the compound represented by formula (I), the pharmaceutically acceptable salts and isomers thereof, and the pharmaceutical compositions containing ...
|
|
WO/2021/003295A1 |
The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclo...
|
|
WO/2021/001739A1 |
The present disclosure relates to novel translational enhancers comprising an eukaryotic initiation factor 4E (eIF4E) ligand attached to a dinucleotide. The present disclosure also relates to RNA molecules (e.g., mRNAs) comprising the no...
|
|
WO/2020/259584A1 |
Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated di...
|
|
WO/2020/260857A1 |
The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
|
|
WO/2020/261156A1 |
Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and dis...
|
|
WO/2020/263253A1 |
Methods of improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in subjects comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalen...
|
|
WO/2020/259528A1 |
A method for preventing, alleviating and/or treating idiopathic pulmonary fibrosis, which comprises administering an effective amount of a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, p...
|
|
WO/2020/261114A1 |
The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms ther...
|
|
WO/2020/255425A1 |
This anti-HBV agent contains a compound represented by general formula (I) or a compound represented by general formula (II), or a salt thereof.
|
|
WO/2020/254473A1 |
Provided herein are compounds of formula (I), pharmaceutical compositions comprising such compounds, and methods of using such compounds through induction of the T helper 1 (Th1) immune response to treat infections, diseases, and disorde...
|
|
WO/2020/256477A1 |
The present invention provides a novel pyrimidine derivative compound and a pharmaceutically acceptable salt thereof, each of which inhibits the growth of cancer cells. The present invention provides a pharmaceutical composition comprisi...
|
|
WO/2020/257180A1 |
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
